Brief: Omega Therapeutics Receives Orphan Drug Designation For Otx-2002 For Treatment Of Hepatocellular Carcinoma
02/11/2022 11:28
Nov 2 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR
OTX-2002
FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
Source text for Eikon: ID:nPnc4sp4sa
Further company coverage: OMGA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence